SoftOx Solutions AS — Capital/Financing Update 2024

Apr 29, 2024

Softox Solutions AS – Close of Subscription Period today

Softox Solutions AS – Close of Subscription Period today

Not for release, publication or distribution, in whole or in part directly or indirectly, in Australia, Canada, Japan or the United States (or any other jurisdiction in which the release, publication or distribution would be unlawful). This announcement does not constitute an offer of any of the securities described herein.

Oslo, 29 April 2024: Reference is made to the stock exchange notice from Softox Solutions AS (the "Company") 15. April 2024 regarding the commencement of the subscription period in the subsequent offering of up to 125,000,000 new shares (the "Subscription Period").

The Subscription Period ends today Monday 29 April 2024 at 16:30 hours (CEST). Subscription rights that are not used to subscribe for Offer Shares before the expiry of the Subscription Period will have no value and will lapse without compensation to the holder.

Please see the Prospectus for more information about the subsequent offering. The Prospectus, including subscription form, is electronically available at www.soft-ox.com and www.sb1markets.no.

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com